Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2023

Earnings data Q2 2023

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Agenus

Hub Cyber Security Ltd

Kinross Gold

Oatly

Protalix Biotherapeutics

QualTek Services

Are these penny stocks to buy now or avoid entirely? The post Penny Stocks To Buy Now: 7 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now: 7 To Watch Before Next Week

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

Energy Vault Holdings

Comscore Inc.

Solid Power

thredUP

Insiders are buying these penny stocks but are they worth the risk? The post 5 Top Penny Stocks To Buy In March According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Buy In March According To Insiders

Fintel reports that Tang Capital Partners has filed a 13D form with the SEC disclosing ownership of 5.30MM shares of Jounce Therapeutics Inc (JNCE).

Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics

Jounce Therapeutics (NASDAQ: JNCE ) stock is climbing higher on Wednesday after getting an unexpected acquisition bid from Concentra Biosciences. That acquisition offer has Concentra Biosciences seeking to acquire JNCE stock for $1.80 per share in cash.

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

SVB Financial Group

Shares of Jounce Therapeutics Inc. JNCE, -6.09% bounced 6.6% in premarket trading Monday, after the immunotherapy company said only about $2.6 million, or 1.4% of its total cash and cash equivalents was in an operating account at SIVB Financial Group's SIVB, -60.41% Silicon Valley Bank, which was shut down last week. Jounce, which had $189.5 million in total cash and cash equivalents as of Dec. 31, said it also holds a $1.3 million letter of credit at SBV.

Jounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating account

NEW YORK , Feb. 27, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Jounce Therapeutics, Inc. (NASDAQ: JNCE), relating to its proposed merger with Redx Pharma. Click here for more information: https://www.monteverdelaw.com/case/jounce-therapeutics-inc.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Jounce Therapeutics, Inc. - JNCE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Jounce Therapeutics, Inc. (the “Company”) (NasdaqGS: JNCE) with Redx Pharma Plc. Under the terms of the proposed transaction, Jounce shareholders will end up owning approximately 37% of the share capital of the combined group.

JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE

Terran Orbital Corp

Vascular Biogenics

Use these tips to make money with penny stocks when day trading The post Maximizing Returns With Penny Stocks: Day Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Maximizing Returns With Penny Stocks: Day Trading

Jounce Therapeutics (NASDAQ: JNCE ) stock is on the rise Thursday after the company revealed merger plans with Redx Pharma . Jounce Therapeutics and Redx Pharma will undergo a merger with an all-stock transaction fueling it.

Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Jounce Therapeutics, Inc. (NASDAQ: JNCE) and Redx Pharma is fair to Jounce shareholders. Halper Sadeh encourages Jounce shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

JNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Jounce Therapeutics, Inc. Is Fair to Shareholders

Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease

Redx and Jounce Announce Recommended Business Combination

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent. The decision to reduce its workforce was made as Jounce believes advancement of its clinical programs, JTX-8064 and vopratelimab, requires funding and a scope that the Company cannot pursue on its own and will be seeking business development opportunities for both programs.

Jounce Therapeutics Announces Restructuring

Jounce has recently announced that it has sold its entire rights to immunotherapy candidate GS-1181 to Gilead for $67 million. I expect the biotech company to now have around $170 million cash, with a market cap of about $55 million.

Jounce: Gilead's GS-1811 Buyout Allows A Further Bounce

Ambev

Cenntro Electric Group Ltd

Innovative Eyewear Inc

Use these tips to read penny stocks market news The post How to Read Penny Stocks News and Use it to Profit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Read Penny Stocks News and Use it to Profit

Gilead Sciences

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

Jounce Therapeutics (NASDAQ: JNCE ) stock jumped after it sold rights to a cancer drug to Gilead Sciences (NASDAQ: GILD ). Shares were trading as high as $1.30 in the pre-market, after closing under 75 cents on Dec. 27.

Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?

Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.

Gilead buys out rights to cancer therapy from Jounce for $67 mln

Jounce Therapeutics Inc. JNCE, -6.66% shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. GILD, +0.31% would completely acquire rights to an immunotherapy drug from Jounce. Gilead said it would buy out its remaining obligations under a licensing agreement executed in 2020 between the two companies and acquire intellectual property and rights to the cancer treatment, known as GS-1811.

Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug

-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- -- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors --

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

FOSTER CITY, Calif. & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020.

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) -

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

Jounce Therapeutics, Inc. (NASDAQ:JNCE ) Q3 2022 Results Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray - Chief Executive Officer and President Hugh Cole - Chief Operating Officer Elizabeth Trehu - Chief Medical Officer Dmitri Wiederschain - Chief Scientific Officer Kim Drapkin - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Boris Peaker - Cowen and Company Edward Tenthoff - Piper Sandler David Dai - SMBC Nikko Yu He - H.C. Wainwright & Co. Colleen Kusy - Robert W.

News for Jounce Therapeutics Stock (JNCE)